Oncotarget

Meta-Analysis:

The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis

Jie Zhang, Hong-Ying Zhang, Jia Li, Xin-Yu Shao and Chun-Xia Zhang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:68837-68846. https://doi.org/10.18632/oncotarget.18575

Metrics: PDF 938 views  |   HTML 1358 views  |   ?  


Abstract

Jie Zhang1, Hong-Ying Zhang2, Jia Li1, Xin-Yu Shao3 and Chun-Xia Zhang1

1Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China

2Department of Pathology and Forensic Medicine, College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, China

3Medical Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, China

Correspondence to:

Chun-Xia Zhang, email: qm1210@hotmail.com

Keywords: colorectal cancer, neutrophils-to-lymphocytes ratio, platelet-to-lymphocytes ratio, platelet counts, prognosis

Received: February 24, 2017     Accepted: May 05, 2017     Published: June 19, 2017

ABSTRACT

Recently, several studies have reported that inflammatory response and elevated platelet counts may be associated with the poor prognosis of colorectal cancer. This meta-analysis was designed to analyze and evaluate the prognostic role of elevated preoperative or pretreatment neutrophils-to-lymphocytes ratio, platelet-to-lymphocytes ratio or platelet counts in patients with colorectal cancer. We searched PubMed, EMBASE, Cochrane Library and Web of Science to April, 2016. A total of 23 studies (N = 11762 participants) were included for this meta-analysis. Elevated neutrophils-to-lymphocytes ratio have a close relationship with the poor Overall Survival of colorectal cancer with the pooled HR being 1.92 [95% CI 1.57–2.34; P < 0.00001]. This meta-analysis indicated that elevated neutrophils-to-lymphocytes ratio, platelet-to-lymphocytes ratio or platelet counts may be a cost-effective and noninvasive serum biomarker for poor prognosis for patients with colorectal cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18575